Gene expression profiling shows that, by gene signature, the difference between BRAF-
positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded …

Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Thyroid carcinomas represent a challenging problem from the prognostic standpoint.
Despite an overall good prognosis of the most frequent endocrine malignancy, 10–15% of …

Over the last decade, investigators have developed a clearer understanding of the genetic
alterations underlying thyroid carcinogenesis. A number of biomarkers involved in the …

Objective To correlate the presence of BRAF V600E mutation with clinicopathological
parameters. Study Design Case-control study. Setting BRAF mutation represents the most …

Summary Purpose BRAF V600E mutation represents the most common oncogenic event in
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …

Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid
carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of …

Context: The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as
a negative prognostic factor is a subject of intense debate. This mutation has been …

The BRAF mutation occurs commonly in papillary thyroid carcinoma (PTC). Previous
investigations of its utility to predict recurrence‐free survival (RFS) and disease‐specific …